Well StudiedWeight LossMetabolic

AOD-9604

hGH Fragment 176-191

Modified hGH Fragment | Fat Loss Peptide

Half-life

3-4 minutes

Chain length

16 amino acids

Reference frequency

Once daily

Research overview

DoseGear research brief

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.

Mechanism of action

Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Modified C-terminal growth-hormone fragment.

What it is researched for

Experimental lipid-metabolism and obesity research with proposed lipolytic and antilipogenic activity.

Research observation window

A cited obese-mouse study used 14 days of intraperitoneal treatment. A human injectable response window is not established.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Fat loss - Standard	250-300mcg	Once daily (morning, fasted)	SubQ
Enhanced fat loss	400-500mcg	Once daily (morning, fasted)	SubQ
Joint support	250mcg	Once daily	SubQ
Conservative start	200mcg	Once daily	SubQ

Reference cycle

8-12 weeks

Reference storage

Lyophilized: room temp or freezer long-term; Reconstituted: 2-8°C for 28 days

Safety context

Reported side effects

Generally well-tolerated in clinical trials
Mild injection site reactions possible
No reported effects on blood glucose or insulin

Contraindications & cautions

Pregnancy or breastfeeding
WADA prohibited - athletes subject to testing must avoid

Scientific references

01
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Scientific citationIncrease of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity (2001).
02
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Scientific citationThe effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology (2001).
03
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Scientific citationMetabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research (2000).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity